

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 38D0628274	(X3) Date Survey Completed 10/16/2023
Name of Provider or Supplier Summit Health City Md	Street Address, City, State 1501 Ne Medical Center Dr, Bend, OR	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on Proficiency Testing (PT) desk review of the American Proficiency Institute (API) proficiency testing and CASPER Report 0155D, and phone conversation with the Technical Supervisor (TS) revealed the laboratory had unsuccessful participation for two (2) out of three (3) testing events for the analyte Digoxin in the specialty Toxicology in 2023. Findings include. 1. API 1st event 2023 = Digoxin 60% 2. API 1st event 2023 = Toxicology 60% 3. API 3rd event 2023 = Digoxin 60% 4. API 3rd event 2023 = Toxicology 60% 5. Phone conversation with the TS confirmed these findings on 10/16/2023 @ 11:30 AM.

D2118	TOXICOLOGY CFR(s): 493.845(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on Proficiency Testing (PT) desk review of the American Proficiency Institute (API) proficiency testing and CASPER Report 0155D, and phone conversation with the Technical Supervisor (TS) revealed the laboratory had unsuccessful participation for two (2) out of three (3) testing events for the analyte Digoxin in 2023. Findings include. 1. API 1st event 2023 = Digoxin 60% 2. API 3rd event 2023 = Digoxin 60% 3. Phone conversation with the TS confirmed these findings on 10/16/2023 @ 11:30 AM.
D2119	TOXICOLOGY CFR(s): 493.845(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on Proficiency Testing (PT) desk review of the American Proficiency Institute (API) proficiency testing and CASPER Report 0155D, and phone conversation with the Technical Supervisor (TS) revealed the laboratory had unsuccessful participation for two (2) out of three (3) testing events for specialty Toxicology in 2023. Findings include. 1. API 1st event 2023 = Toxicology 60% 2. API 3rd event 2023 = Toxicology 60% 5. Phone conversation with the TS confirmed these findings on 10/16/2023 @ 11:30 AM.